Everest Medicines Announces Exclusive Licensing Deal with Dimerix for DMX-200 in Asia-Pacific
Everest Medicines Limited (HKEX: 1952) has entered into a significant agreement with Dimerix Limited (ASX: DXB), granting Everest Medicines an exclusive license to develop and commercialize DMX-200 across Greater China, South Korea, and select Southeast Asian markets. This strategic move, announced on 16 June 2026, marks a major expansion of Everest Medicines’ nephrology pipeline and positions the company as a leading player in kidney and autoimmune disease therapeutics in Asia.
Key Highlights of the Agreement
- Exclusive Regional Rights: Everest has secured the exclusive rights for DMX-200, a small molecule inhibitor targeting chemokine receptor 2 (CCR2), currently in a pivotal Phase 3 clinical trial (ACTION3) for the treatment of Focal Segmental Glomerulosclerosis (FSGS).
- Orphan Drug Status: DMX-200 has received orphan drug designations from both the U.S. FDA and the European Medicines Agency (EMA), highlighting its potential as a novel therapy for a rare and serious kidney disorder.
- Financial Terms: The deal features a combination of upfront, milestone, and royalty payments:
- Upfront Payment: US\$10 million
- Development & Regulatory Milestones: Up to US\$30 million in potential payments
- Sales Milestones: Up to US\$300 million in potential payments
- Tiered Royalties: Between 10% to 15% of annual net sales
Key Details For Investors & Shareholders
- Strategic Portfolio Synergy: The addition of DMX-200 is expected to significantly strengthen Everest’s nephrology product portfolio and reinforce its position in the kidney and autoimmune disease market.
- Potential Share Price Impact: The large-scale financial commitment, particularly the potential for US\$300 million in sales milestones and up to 15% royalties, could be highly accretive if the drug succeeds in clinical trials and achieves commercial success.
- Regulatory and Reporting Exemption: The transaction size is below 5% of the relevant ratios under Hong Kong listing rules, so it is exempt from reporting, announcement, and shareholder approval requirements under Chapter 14.
- Clinical and Market Potential: FSGS is a serious and often treatment-resistant kidney disease. Orphan drug designation in the U.S. and Europe may provide market exclusivity and regulatory support, enhancing the commercial potential of DMX-200.
- Technology Platform: DMX-200 was discovered using Dimerix’s proprietary Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable platform that enables novel drug discovery through advanced receptor interaction analysis.
About Dimerix (ASX: DXB)
Dimerix is an Australian clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and kidney diseases. Its lead product, DMX-200, is in Phase 3 development for FSGS. The company leverages its proprietary Receptor-HIT technology to identify and develop novel drug candidates.
Board and Executive Leadership
The Everest Medicines board is chaired by Mr. Yifang Wu (Chairman and Executive Director), with Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, along with a team of non-executive and independent non-executive directors.
Conclusion
This licensing agreement is a potentially transformative transaction for Everest Medicines, expanding its late-stage pipeline with a promising asset in a high-need area. The financial structure, regulatory support, and market exclusivity make it a newsworthy event that may positively influence the company’s share price, especially if DMX-200 achieves regulatory and commercial milestones.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. Everest Medicines’ financial performance and share price may be affected by the progress of DMX-200’s clinical trials, regulatory approvals, and market adoption, as well as other factors not discussed here.
粵語版本 (Cantonese Version)
雲頂醫藥獲Dimerix獨家授權，推進DMX-200於亞洲市場業務
雲頂醫藥有限公司（港交所：1952）宣佈，已於2026年6月16日與澳洲證券交易所上市公司Dimerix Limited（ASX: DXB）簽訂一項重大協議，獲得DMX-200於大中華、南韓及部分東南亞市場的獨家開發及商業化權利。此舉標誌著雲頂醫藥腎科產品管線進一步擴展，並鞏固其在腎臟及自身免疫疾病治療領域的領先地位。
協議重點
- 獨家區域權利： 雲頂醫藥獲得DMX-200於指定亞洲市場的獨家權利。DMX-200是一種針對化學趨化因子受體2（CCR2）的小分子抑制劑，現正於名為ACTION3的關鍵三期臨床試驗中，用於治療局灶節段性腎小球硬化症（FSGS）。
- 孤兒藥資格： DMX-200已獲美國食品藥品監督管理局（FDA）及歐洲藥品管理局（EMA）授予孤兒藥資格，突顯該藥物在罕見腎病治療方面的潛力。
- 財務條款：
- 首期付款： 1,000萬美元
- 開發及監管里程碑： 最高3,000萬美元
- 銷售里程碑： 最高3億美元
- 分級權利金： 按年度淨銷售額收取10%-15%權利金
投資者及股東須知的關鍵資訊
- 戰略協同效應： DMX-200的加入有望大幅增強雲頂醫藥腎科產品組合，並鞏固其在腎臟及自身免疫疾病市場的戰略地位。
- 潛在股價影響： 若DMX-200臨床及商業化進展順利，協議中的高額銷售里程碑及最高15%權利金，有機會大幅提升公司財務表現，對股價產生正面影響。
- 監管及報告豁免： 由於交易規模未達香港上市規則第14章的5%標準，故本次交易免於公告及股東批准要求。
- 臨床及市場潛力： FSGS是一種嚴重且治療困難的腎病。DMX-200獲孤兒藥資格，有望獲得市場專利保護及監管支持，為其商業潛力加分。
- 技術平台： DMX-200由Dimerix專有的受體異源體調查技術（Receptor-HIT）平台發現，具備大規模及全球應用潛力，有助於發掘新型藥物。
關於Dimerix（ASX: DXB）
Dimerix是一家澳洲臨床階段生物製藥公司，專注於炎症及腎臟疾病新療法的開發。其主力產品DMX-200現正進行FSGS三期臨床試驗。公司利用專有的Receptor-HIT技術，發掘並開發新型藥物。
董事會及管理層
雲頂醫藥董事會由吳一方先生擔任主席及執行董事，羅永慶及胡英穎擔任執行董事，另有非執行及獨立非執行董事組成。
總結
本次獨家授權協議對雲頂醫藥而言是一次具潛力的關鍵交易，為公司帶來一項在高度需求領域具備潛力的後期研發資產。協議的財務結構、監管支持及市場專利保護，有望推動公司未來發展及股價表現，特別是在DMX-200臨床及商業化取得突破時。
免責聲明： 以上內容僅供參考，並不構成任何投資建議。投資者應自行進行研究及諮詢專業意見，方作出投資決策。雲頂醫藥的財務表現及股價可能受DMX-200臨床進度、監管批核及市場接受程度等因素影響，亦可能受其他未述及因素所影響。
